Quest Diagnostics has been actively advancing within the diagnostic field, with several acquisitions, corporate reshuffles, stock adjustments by various asset management companies, as well as a few underperformances compared to competitors. PathAI Diagnostics' labs were acquired by Quest Diagnostics to boost AI in cancer diagnosis. Despite underperforming at times against competitors, the stock's recent underperformance seems not to be influenced by its fundamentals. They have continued to increase their presence and capabilities in various sectors of the medical field, launching a melanoma risk prediction test, and a regulatory approved adeno-associated test. They have also announced collaborations with Instacart, to combat food insecurity, and with Scipher Medicine, to improve access for Rheumatoid patients. Earnings reports indicate a favorable outlook for 2024, following mixed results in 2023. Their recently launched mobile phlebotomy service and their continuation of a collaboration with the CDC are signs that the company is looking towards increased innovation and service delivery.
Quest Diagnostics DGX News Analytics from Wed, 30 Aug 2023 07:00:00 GMT to Sun, 16 Jun 2024 11:40:38 GMT -
Rating 6
- Innovation 5
- Information 5
- Rumor 3